Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Curious as to what your latest streaming bundle will look like? Find out what the future of media looks like from Ken Leon, Research Director, at CFRA. Watch!
Nathan Bomey, Reporter at Axios, discusses where Tesla stands, Musk's relationship with the incoming president and expectations for Tesla throughout 2025.
Senior Writer at Fast Company, Elizabeth Segran, discusses how Sephora has become the dominant beauty retailer and why brands want to sell there. Watch!
Matt Calkins, CEO of Appian, breaks down the recent bipartisan report on AI safety and shares thoughts on future privacy enhancements needed in the space.
